

Claims

1-25 (canceled)

26. (previously presented) A method for treating a subject having a neoplastic disorder comprising administering to the subject a composition comprising an anti-caveolin antibody wherein the antibody is effective to inhibit metastasis in the neoplastic disorder.

27. (previously presented) The method of claim 26, wherein the neoplastic disorder is a dysplasia.

28. (previously presented) The method of claim 26, wherein the neoplastic disorder is hyperplasia, dysplasia or a hypertrophy.

29. (previously presented) The method of claim 26, wherein the neoplastic disorder is benign enlargement of the prostate, nodular hyperplasia or benign prostatic hypertrophy.

30. (previously presented) The method of claim 26, wherein the neoplastic disorder is a malignancy.

31. (previously presented) The method of claim 26, wherein the neoplastic disorder is hormone responsive.

32. (currently amended) The method of claim 26, wherein the subject neoplastic disorder is a cancer patient.

33. (currently amended) The method of claim 26, wherein the subject neoplastic disorder is a prostate cancer patient.

34. (currently amended) The method of claim 26, wherein the subject neoplastic disorder is a breast cancer patient.

35. (previously presented) A method for treating a neoplastic disease of the prostate comprising administering to a subject in need thereof an anti-caveolin agent in conjunction with androgen ablation therapy.

36. (previously presented) The method of claim 35, wherein the anti-caveolin agent is an anti-caveolin antibody.

37. (previously presented) The method of claim 35, wherein the antibody is a monoclonal antibody.

38. (previously presented) The method of claim 35, wherein the antibody is a polyclonal antibody.

39. (previously presented) The method of claim 35, wherein the androgen ablation therapy comprises administration of a composition comprising an anti-androgen antibody to the subject.

40. - 105. (canceled)